In tumor immunotherapy utilizing these IL-33-induced FCGR3+CD103+ cDC1s, tumor growth in solid tumor models or lung metastasis tumor models is significantly suppressed compared to that in control cDC1s or GM-CSF-induced CD103+ cDC1s31. This evidence concerns the gene IL33 and neoplasm.